Category Archives: Stem Cell Research

One of the key reasons for adoption of flow cytometry technology is its precise deliverance of results comparing to conventional methods such as ELISA. The emergence of this technology as one of the leading applications has brought various advancements in the diagnosis of diseases such as HIV and cancer as well as in research fields. With rising advancements in information technology, it finds application in drug discovery and development. Moreover, it is now used in hematopoietic stem cell research, multiparameter analysis and pharmacogenesis. Increase in research & development in life sciences has boosted flow cytometry technology market. This market has recently evidenced significant advancements such as cytometers with varying detectors and lasers, which would enable labelling of multiple antibodies and instruments capable of capturing digital images.

Flow cytometry market which is valued $3000 million in 2012, is expected to reach a value of $6530 million by 2020, experiencing a CAGR of 30.9%.

Request To Download Sample of This Strategic Report:-https://reportocean.com/industry-verticals/sample-request?report_id=26910

Market Statistics:

The file offers market sizing and forecast throughout 5 primary currencies USD, EUR GBP, JPY, and AUD. It helps corporation leaders make higher choices when foreign money change records are available with ease. In this report, the years 2020 and 2021 are regarded as historic years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2030 are viewed as the forecast period.

The Centers for Medicare and Medicaid Services report that US healthcare expenditures grew by 4.6% to US$ 3.8 trillion in 2019, or US$ 11,582 per person, and accounted for 17.7% of GDP. Also, the federal government accounted for 29.0% of the total health expenditures, followed by households (28.4%). State and local governments accounted for 16.1% of total health care expenditures, while other private revenues accounted for 7.5%.

This study aims to define market sizes and forecast the values for different segments and countries in the coming eight years. The study aims to include qualitative and quantitative perspectives about the industry within the regions and countries covered in the report. The report also outlines the significant factors, such as driving factors and challenges, that will determine the markets future growth.

Though, increase in application has widened the scope of flow cytometry market, the cost of the instrument is impeding the growth. Moreover, advancing technologies has brought in complex instrumentation that requires highly skilled personals to operate. North America accounted for the largest share of global flow cytometry market revenue in 2012. However, Asia Pacific & RoW market is expected to have the highest growth rate of 10.6% during the analysis period and is expected to be the fastest growing market.

Get a Request Sample Report:https://reportocean.com/industry-verticals/sample-request?report_id=26910

MARKET SCOPE

Flow cytometry measures and analyzes cells of various characterizations, through a light beam that is passed through a suspension of fluid. Several properties of the cell structure and functions can be studied by labelling or non-labelling of antibodies with the help of this technique. Various factors such as protein synthesis, DNA content, RNA content, surface receptors and many more factors can be analyzed by this technology.

The scope of this report is to identify potential flow cytometry market on the basis of products, technology, application and end users

Flow cytometry as defined in this report is associated with the clinical and research fields and is used in diagnosis of certain diseases (cancer, HIV, etc.) and research (drug development and stem cell research)

The flow cytometry market in this report does not merely explain the applications of flow cytometry but also elucidates how it has replaced other conventional methods.

The report analyses the global flow cytometry market by geography, segmenting the market as North America, Europe and Asia Pacific & RoW. The emerging economies such as Asia Pacific and RoW are expected to grow due to the demand for better health care.

KEY DELIVERABLES

In the current scenario, instruments market has the highest revenue share in the total flow cytometry market. This segment is further expected to remain as the highest revenue generator during the analysis period. Increase in modularity, accessibility, imaging capabilities, availability of wavelengths and targets and size reduction are few of the significant trends in the market, assisting in adoption of these instruments by the end users. Though instruments market is at the peak in terms of revenue, reagents market is expected to experience the highest growth rate of CAGR 12%, during the analysis period. Ready to use kits is another driving factor for this market, as these reagents are easy to use and have applications in areas such as cancer diagnosis and drug discovery. These kits avoid the cost of transportation in cold storage, errors while manual pipetting of liquid reagents and the loss associated with the liquid sample degradation in high room temperature during processing, thus benefitting resource poor countries.

The flow cytometry market is segmented as follows:

PRODUCT:

FC instrumentsReagentsConsumablesSoftwareServicesAccessories

TECHNOLOGY:

Cell based TechnologiesBead-based Technologies

APPLICATION

ClinicalApoptosisCell Cycle AnalysisCell sortingCell ViabilityResearch FieldsOrgan transplantationCancerImmunodeficiency DiseaseHematology Haematological Malignancies

Request full Report-https://reportocean.com/industry-verticals/sample-request?report_id=26910

END USERS

Commercial OrganizationsHospitalsAcademic InstitutesMedical SchoolsClinical Testing LabsOthers

GEOGRAPHY

North AmericaEuropeAsia PacificRoW

Table of Content:

Key Questions Answered in the Market Report

How did the COVID-19 pandemic impact the adoption of by various pharmaceutical and life sciences companies? What is the outlook for the impact market during the forecast period 2021-2030? What are the key trends influencing the impact market? How will they influence the market in short-, mid-, and long-term duration? What is the end user perception toward? How is the patent landscape for pharmaceutical quality? Which country/cluster witnessed the highest patent filing from January 2014-June 2021? What are the key factors impacting the impact market? What will be their impact in short-, mid-, and long-term duration? What are the key opportunities areas in the impact market? What is their potential in short-, mid-, and long-term duration? What are the key strategies adopted by companies in the impact market? What are the key application areas of the impact market? Which application is expected to hold the highest growth potential during the forecast period 2021-2030? What is the preferred deployment model for the impact? What is the growth potential of various deployment models present in the market? Who are the key end users of pharmaceutical quality? What is their respective share in the impact market? Which regional market is expected to hold the highest growth potential in the impact market during the forecast period 2021-2030? Which are the key players in the impact market?

Inquire or Share Your Questions If Any Before the Purchasing This Report

https://reportocean.com/industry-verticals/sample-request?report_id=26910

About Report Ocean:We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATESTel:+1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com

Originally posted here:
Flow Cytometry Market is Estimated Drive the Industry Growth Across World in Coming Year 2030 Queen Anne and Mangolia News - Queen Anne and Mangolia...

Share this Article

You are free to share this article under the Attribution 4.0 International license.

A miniature replica of a heart chamber built from a combination of nanoengineered parts and human heart tissue offers a new way to study the heart.

Theres no safe way to get a close-up view of the human heart as it goes about its work: you cant just pop it out, take a look, then slot it back in.

Scientists have tried different ways to get around this fundamental problem: theyve hooked up cadaver hearts to machines to make them pump again, attached lab-grown heart tissues to springs to watch them expand and contract. Each approach has its flaws: reanimated hearts can only beat for a few hours; springs cant replicate the forces at work on the real muscle.

But getting a better understanding of this vital organ is urgent. In America, someone dies of heart disease every 36 seconds, according to the Centers for Disease Control and Prevention.

The new miniature replica of a heart chamber has no springs or external power sourceslike the real thing, it just beats by itself, driven by the live heart tissue grown from stem cells. The device could give researchers a more accurate view of how the organ works, allowing them to track how the heart grows in the embryo, study the impact of disease, and test the potential effectiveness and side effects of new treatmentsall at zero risk to patients and without leaving a lab.

The team behind the gadgetnicknamed miniPUMP, and officially known as the cardiac miniaturized Precision-enabled Unidirectional Microfluidic Pumpsays the technology could also pave the way for building lab-based versions of other organs, from lungs to kidneys.

We can study disease progression in a way that hasnt been possible before, says Alice White, a professor and chair of mechanical engineering at the Boston University College of Engineering. We chose to work on heart tissue because of its particularly complicated mechanics, but we showed that, when you take nanotechnology and marry it with tissue engineering, theres potential for replicating this for multiple organs.

The device could eventually speed up the drug development process, making it faster and cheaper, the researchers say. Instead of spending millionsand possibly decadesmoving a medicinal drug through the development pipeline only to see it fall at the final hurdle when tested in people, researchers could use the miniPUMP at the outset to better predict success or failure.

The project is part of CELL-MET, a multi-institutional National Science Foundation Engineering Research Center in Cellular Metamaterials thats led by Boston University. The centers goal is to regenerate diseased human heart tissue, building a community of scientists and industry experts to test new drugs and create artificial implantable patches for hearts damaged by heart attacks or disease.

Heart disease is the number one cause of death in the United States, touching all of us, says White. Today, there is no cure for a heart attack. The vision of CELL-MET is to change this.

Theres a lot that can go wrong with your heart. When its firing properly on all four cylinders, the hearts two top and two bottom chambers keep your blood flowing so that oxygen-rich blood circulates and feeds your body. But when disease strikes, the arteries that carry blood away from your heart can narrow or become blocked, valves can leak or malfunction, the heart muscle can thin or thicken, or electrical signals can short, causing too manyor too fewbeats. Unchecked, heart disease can lead to discomfortlike breathlessness, fatigue, swelling, and chest painand, for many, death.

The heart experiences complex forces as it pumps blood through our bodies, says Christopher Chen, professor of biomedical engineering. And while we know that heart muscle changes for the worse in response to abnormal forcesfor example, due to high blood pressure or valve diseaseit has been difficult to mimic and study these disease processes. This is why we wanted to build a miniaturized heart chamber.

At just 3 square centimeters, the miniPUMP isnt much bigger than a postage stamp. Built to act like a human heart ventricleor muscular lower chamberits custom-made components are fitted onto a thin piece of 3D-printed plastic. There are miniature acrylic valves, opening and closing to control the flow of liquidwater, in this case, rather than bloodand small tubes, funneling that fluid just like arteries and veins. And beating away in one corner, the muscle cells that make heart tissue contract, cardiomyocytes, made using stem cell technology.

Theyre generated using induced pluripotent stem cells, says Christos Michas, a postdoctoral researcher who designed and led the development of the miniPUMP as part of his PhD thesis.

To make the cardiomyocyte, researchers take a cell from an adultit could be a skin cell, blood cell, or just about any other cellreprogram it into an embryonic-like stem cell, then transform that into the heart cell.

In addition to giving the device literal heart, Michas says the cardiomyocytes also give the system enormous potential in helping pioneer personalized medicines. Researchers could place a diseased tissue in the device, for instance, then test a drug on that tissue and watch to see how its pumping ability is affected.

With this system, if I take cells from you, I can see how the drug would react in you, because these are your cells, says Michas. This system replicates better some of the function of the heart, but at the same time, gives us the flexibility of having different humans that it replicates. Its a more predictive model to see what would happen in humanswithout actually getting into humans.

That could allow scientists to assess a new heart disease drugs chances of success long before heading into clinical trials, Michas says. Many drug candidates fail because of their adverse side effects.

At the very beginning, when were still playing with cells, we can introduce these devices and have more accurate predictions of what will happen in clinical trials. It will also mean that the drugs might have fewer side effects.

One of the key parts of the miniPUMP is an acrylic scaffold that supports, and moves with, the heart tissue as it contracts. A series of superfine concentric spiralsthinner than a human hairconnected by horizontal rings, the scaffold looks like an artsy piston. Its an essential piece of the puzzle, giving structure to the heart cellswhich would just be a formless blob without itbut not exerting any active force on them.

We dont think previous methods of studying heart tissue capture the way the muscle would respond in your body, says Chen, whos also director of Boston Universitys Biological Design Center and an associate faculty member at Harvard Universitys Wyss Institute for Biologically Inspired Engineering. This gives us the first opportunity to build something that mechanically is more similar to what we think the heart is actually experiencingits a big step forward.

To print each of the tiny components, the team used a process called two-photon direct laser writinga more precise version of 3D printing. When light is beamed into a liquid resin, the areas it touches turn solid; because the light can be aimed with such accuracyfocused to a tiny spotmany of the components in the miniPUMP are measured in microns, smaller than a dust particle.

The decision to make the pump so small, rather than life-size or larger, was deliberate and is crucial to its functioning.

The structural elements are so fine that things that would ordinarily be stiff are flexible, says White. By analogy, think about optical fiber: a glass window is very stiff, but you can wrap a glass optical fiber around your finger. Acrylic can be very stiff, but at the scale involved in the miniPUMP, the acrylic scaffold is able to be compressed by the beating cardiomyocytes.

The pumps scale shows that with finer printing architectures, you might be able to create more complex organizations of cells than we thought was possible before, Chen says.

At the moment, when researchers try to create cells, he says, whether heart cells or liver cells, theyre all disorganizedto get structure, you have to cross your fingers and hope the cells create something. That means the tissue scaffolding pioneered in the miniPUMP has big potential implications beyond the heart, laying the foundation for other organs-on-a-chip, from kidneys to lungs.

An electrical and computer engineering student as an undergraduate, Michas says hed never seen cells in my life before starting this project. Now, hes preparing to start a new position with Seattle-based biotech Curi Bio, a company that combines stem cell technology, tissue biosystems, and artificial intelligence to power the development of drugs and therapeutics.

Christos is someone who understands the biology, says White, can do the cell differentiation and tissue manipulation, but also understands nanotechnology and whats required, in an engineering way, to fabricate the structure.

The next immediate goal for the miniPUMP team? To refine the technology. They also plan to test ways to manufacture the device without compromising its reliability.

There are so many research applications, says Chen. In addition to giving us access to human heart muscle for studying disease and pathology, this work paves the way to making heart patches that could ultimately be for someone who had a defect in their current heart.

The study is published in Science Advances. Additional coauthors are from Florida International University and Boston University.

Source: Andrew Thurston for Boston University

Read more:
Mini-heart chamber beats on its own just like the real thing - Futurity: Research News

Scientists largely agree that stem cells may hold a key to the treatment, and even cure, of many serious medical conditions. But while the use of adult stem cells is widely accepted, many religious groups and others oppose stem cell research involving the use and destruction of human embryos. At the same time, many scientists say that embryonic stem cell research is necessary to unlock the promise of stem cell therapies since embryonic stem cells can develop into any cell type in the human body.

In late 2007, researchers in the United States and Japan succeeded in reprogramming adult skin cells to act like embryonic stem cells. The new development offers the possibility that the controversy over the use of embryos could end. But many scientists and supporters of embryonic stem cell research caution that this advance has not eliminated the need for embryos, at least for the time being.

Recently, the Pew Forum sat down with Yuval Levin, author of Tyranny of Reason, to discuss the ethical and moral grounds for opposing embryonic stem cell research. Previously, Levin was the executive director of the Presidents Council on Bioethics. Currently, he is the Hertog Fellow at the Ethics and Public Policy Center in Washington, D.C., where he also directs the centers Bioethics and American Democracy program.

A counterargument explaining the case for embryonic stem cell research is made by Jonathan Moreno, a professor at the University of Pennsylvania and a senior fellow at the Center for American Progress in Washington, D.C.

Featuring:Yuval Levin, Hertog Fellow and Director of the Bioethics and American Democracy Program, Ethics and Public Policy Center

Interviewer:David Masci, Senior Research Fellow, Pew Forum on Religion & Public Life

Recently, researchers in the United States and Japan successfully turned human skin cells into cells that behave like embryonic stem cells. There has been some discussion that this advance makes the moral and ethical debate over embryonic stem cells moot. Do you think thats an accurate assessment?

I think its going to take a while for the ethical debate to catch up with the science. The scientific community has reacted very positively to this advancement, which was made in November 2007. There have been many additional scientific studies published on the topic since then, and it appears increasingly likely that the cells produced using skin cells are the equivalent of embryonic stem cells. So I think that, in time, this probably will be the final chapter of this particular debate about embryonic stem cells, but I dont think were at the end of it quite yet.

Do you agree with Professor James Thomson, who led the American research team that made this breakthrough, when he maintains that this advance does not, for the time being, abrogate the need for embryonic stem cell research?

Part of his argument for continuing to use embryonic stem cells was backward-looking to make the point that researchers wouldnt have been able to develop this technique if they hadnt been doing embryonic stem cell research. I think thats true, although in a certain way it actually vindicates the logic of President Bushs stem cell policy, which is to allow some work to be done without creating an incentive for the destruction of further embryos to advance the basic science in these kinds of directions.

Thomson also argued that there will still be a need to use embryos in the future. I think thats also a fair argument in the sense that there are always interesting things to learn from different kinds of experiments, but it doesnt address the ethical issues surrounding the debate. If there were no ethical concerns, then certainly the new development wouldnt mean embryonic research would become totally useless. But given that there are concerns, the case for destroying embryos does become a lot weaker. For some people, myself included, the ethical concerns are matters of principle and dont change with new developments.

But for a lot of people, the stem cell debate has always been a matter of balance. People are aware that there are ethical concerns and that there is enormous scientific promise. Now the debate is: Given the ethical questions at stake, is the scientific promise sufficient to make us put the ethical concerns aside and support the research? I think that balance has changed because of this advance, and having an alternative to embryonic stem cell research that achieves the same result will obviously affect the way people think about the ethics of this issue.

That doesnt mean the scientists no longer have any use for embryonic stem cells or even that they wont have any use for them. But I do think it means that people are going to change the way they reason about the balance between science and ethics because of this advance.

I know that you believe that human embryos have intrinsic worth. Do you believe that they have the same intrinsic worth as a five-year-old child or a 50-year-old man?

The question of intrinsic worth is complicated. I dont think it is right to try to determine an embryos intrinsic worth by debating when human life begins. The question of when life begins is a biological question, and the answer actually is fairly straightforward: The life of an organism begins at conception. The ethical question, however, is not about when a life begins but whether every life is equal, and thats a very different question.

I think that the embryonic stem cell debate is ultimately about the question of human equality. The United States has had one answer to that question written in its birth certificate the Declaration of Independence which states that all men are created equal. I think that examining this principle of human equality provides the right answer to this debate, but it is not a simple answer. Human equality doesnt mean that every person is the same or that every person can even be valued in the same way on every scale. What it means is that our common humanity is something that we all share. And what that means, in turn, is that we cant treat a human being in certain ways that we might non-human beings.

The protection of human life comes first. And to the extent that the debate is about whether it is acceptable to destroy a living human being for the purpose of science even for the purpose of helping other human beings I think that in that sense, the embryo is our equal. That doesnt mean that I would think of an embryo in the same way that I would think of a three-year-old child, but I would reject a technique that uses either of them for scientific experimentation.

So in other words, even though you would grieve the death of a 50-year-old man more than a five-day-old embryo, on at least the most basic level you believe that they both have the same right to life.

Yes, thats right. And right to life derives from human equality. The right to life is, in a way, drawn out of the political vocabulary of the Declaration of Independence. And so, to my mind, the argument at the heart of the embryonic stem cell debate is the argument about human equality.

Recently in The New Republic magazine, Harvard psychologist Steven Pinker wrote that conservative bioethicists like yourself consistently predict the worst when looking at developments in biotechnology. He went on to say that had there been a presidents council on cyber-ethics in the 1960s, no doubt it would have decried the threat of the Internet since it would inexorably lead to 1984 or computers taking over like HAL in 2001. How do you respond to this suggestion that there always seems to be this sort of chorus of doomsayers every time something new comes along?

To my mind, biotechnology is fundamentally different from past developments in technology because its directed to the human person. From the beginning of the scientific revolution, science and technology have tried to allow us to manipulate and shape the world around us for the benefit of man. Now that were beginning to manipulate and shape man, the question is: For the benefit of what? In some cases thats easy to see. Obviously curing disease is more of an old-fashioned scientific pursuit. But there are newer scientific developments, such as certain types of human enhancement technologies that raise very complicated questions of how we should judge the ends and the means of technological advancements. That being said, Pinker has a point, in a larger sense that judging the risks of new technologies is very difficult. In general, I think we ought to give the benefit of the doubt to our ability to use new technologies. I dont think that we should assume that the worst will happen. But there are specific instances, which are few but very important, when we do need to be cautious.

Lets shift gears to a question about religion and faith. Obviously there are people of faith on both sides of this debate. In fact, there are conservatives traditional social conservatives, such as Republican Sen. Orrin Hatch of Utah who support embryonic stem cell research. But could you explain how the Judeo-Christian and Western moral ethic informs your views on this issue and why you think that God is ultimately on your side?

Well, I dont know that I think that. My approach to this is not religious. Im not a particularly religious person and I come at this from more of a liberal democratic concern for human equality and the foundations of our society. That being said, those foundations are not utterly secular, and my understanding of them is not utterly secular. I think that to believe in human equality you do have to have some sense of a transcendent standard by which to make that judgment. In other words, when we talk about equality, what do we mean? Equal in relation to what?

Some people have certainly tried to make a purely secular liberal argument for human equality. While I think its very hard to ground a genuine, deep belief in human equality in a worldview that sees nothing above the material, I dont think that that belief depends on specific theological commitments. To my mind, its an American belief more than it is a religious belief.

Certainly I think that President Bushs commitment to human equality has a lot to do with a particular Christian sense of human worth and human value. But I dont think that its necessary to ground yourself in a particular theological or sectarian preference. I think that this is really about whether we believe in a liberal society, which comes from a belief in human equality. The American left, which for the most part is on the other side of this debate from where I am, has always been the champion of human equality, and I think that its a question that they have to really think about.

The Pew Forum and the Pew Research Center for the People & the Press have done polling on this issue over the last six or seven years and have found that Americans generally favor embryonic stem cell research. Why do you think this has happened, and what do you think this trend indicates?

Thats an interesting question. We actually did a poll here at the Ethics and Public Policy Center in February on a similar question, and the lesson I drew from that, and from some other polling thats been done, is that on the stem cell debate, people are just very confused about the facts, and the trend lines have generally followed the sense that cures are coming. In the end, the issue has been misrepresented as a choice between cures and Christianity, and people increasingly think that curing people like Christopher Reeve is just as much of a human good as protecting an embryo that they cant even imagine.

But when you dig down into peoples views about stem cell research, you find a great deal of confusion, and when you put the questions in ethical terms, you find small majorities opposing it. When you put the question in medical terms, you find, I think, somewhat larger majorities supporting it. In our poll, we asked the same people a series of questions that basically put the same issue in several different ways, and their responses are total opposites of one another. The fact that the same people come out on the opposite sides of the same issue when its put in different ways suggests to me that the issue is very hard to understand which it is.

Frequently one hears that, ultimately, you cant stop science or progress and that ethical, moral and religious objections inevitably will fall by the wayside when there are clear material gains to be made. Do you think thats the most likely scenario in this case, assuming the scientific community continues to see a need for embryonic stem cell research?

Well, thats the big assumption, right? To my mind, the aim of people such as myself has always been to find ways of doing the science without violating the ethics rather than to force a choice between the science and the ethics. If we force that choice, I think its more likely that the country would choose science over ethics, and thats exactly why we have to avoid the choice. I dont think we should be overconfident in our ability to persuade people to pass up a material benefit for an ethical principle, although I hope that can be done in the stem cell research debate. It certainly has been done in some instances when the principle was more evident and more obvious such as imposing limits on human subject research.

Again, the aim from my point of view and from a lot of people on my side of this argument has been to find ways to advance the science without violating the ethics. Thats the logic of President Bushs stem cell policy; thats why people have been pushing for alternatives; thats why theyre encouraging the development of these latest alternatives to avoid the choice, not to force the choice. I think thats the best thing for the country, from everybodys point of view. You dont want a situation where youve got sort of red-state medicine and blue-state medicine and people believe that the treatment their hospital is giving them is obtained in unethical ways. That would begin to break up the practice of medicine and to affect our attitudes about science which on the whole has done a tremendous amount of good for society. So I think what everybody should aim for is finding a way to end this potentially very damaging debate rather than force a choice.

This transcript has been edited for clarity, spelling and grammar.

See more here:
The Case Against Embryonic Stem Cell Research: An ...

Zincs immune-boosting properties are well-established, but scientists havent known exactly how it works. In a new study published online March 25 in the journal Blood, Fred Hutchinson Cancer Research Center scientists reveal two ways the mineral supports immunity and suggest how it could be used to improve health.

Using mice, the team discovered that zinc is needed for the development of disease-fighting immune cells called T cells and prompts regeneration of the thymus, the immune organ that produces T cells.

This study adds to our knowledge of what zinc is actually doing in the immune system and suggests a new therapeutic strategy for improving recovery of the immune system, said senior author Dr. Jarrod Dudakov, an immunologist at Fred Hutch.

The study also revealed that an experimental compound that mimics zincs action in this organ works even better than the natural mineral to promote immune recovery.

We are now looking into how zinc may fit in with our other discoveries of how the immune system repairs itself and could eventually lead to therapies to improve immune function for people who receive a blood stem cell transplant for a blood cancer or people with chronic immune decline that accompanies aging, Dudakov said.

Thymic regeneration and immune function, and zinc

Previously, Dudakov and his team have outlined the molecular pathways and cell types that govern how the immune systems thymus repairs itself after injury. Such treatments could improve vaccine efficacy and hasten thymic regeneration after stressors like chemotherapy, blood stem cell transplant and radiation exposure.

Dudakov began studying zinc a few years ago when Dr. Lorenzo Iovino, the studys first author and a research associate at Fred Hutch, joined Dudakovs lab. Since the scientists knew that low levels of zinc are linked to fewer infection fighting T cells and a shrunken thymus, where T cells develop, Dudakov and Iovino explored how to supplement with zinc in mouse models where the immune system is damaged.

Iovino, whos also a blood stem cell transplant physician, had shown in a previous study that zinc could boost immune recovery in patients undergoing stem-cell transplants for the blood cancer multiple myeloma.

But the study didnt explain why zinc was helping.

Zinc is critical for T-cell development and thymic regeneration

As in humans, Iovino and Dudakov found that the thymuses of mice deprived of dietary zinc shrink and produce notably fewer mature T cells, even after as little as three weeks of a no-zinc diet. Iovino was able to show that without zinc, T cells cannot fully mature.

He also found that zinc deficiency slows recovery of T-cell numbers after mice receive immune-destroying treatments akin to those given to patients about to receive a blood stem cell transplant.

Conversely, extra zinc speeds this process, and T cells recover faster than normal. The team saw a similar result in a mouse model of blood stem cell transplant.

So we had a consistent result of a better reconstitution of the thymus and also a better reconstitution of T cells in the peripheral blood after zinc supplementation, Iovino said. But we still didnt know how exactly zinc was working.

Iovino discovered that it was the change in zinc levels around cells that release a key regenerative factor that seemed to kick off the thymus renewal processes. T cells accumulate zinc as they develop, but release it after a damaging event like a burst of radiation kills them off.

Cells use a molecule called GPR39 to sense a change in external zinc, and Iovino found that an experimental compound that mimics rising external zinc levels by stimulating GPR39 could also promote renewal factor release and thymic regeneration.

What we think is going on is, as you give zinc supplementation, that gets accumulated within the developing T cells. It gets stored and stored and stored, then the damage comes along and the zinc is released, Dudakov said. Now you have more zinc than you normally would, and it can instigate this regenerative pathway. With the experimental compound we can just directly target GPR39 and basically get the same effect without any of that pretreatment.

Getting to the clinic

Theres still a lot to learn before they can turn their findings to therapeutic strategies, the scientists said.

Transplant patients already receive mineral supplements, so if extra zinc were to be incorporated into their treatment regimens, it would be important to make sure that anyone receiving it is truly zinc-deficient. Iovino thinks many patients might be, but right now there isnt a good test to assess this. Hes currently working on developing one, which would first be used to help researchers determine whether patients zinc status correlates with immune recovery after blood stem cell transplant.

Dudakov will pursue GPR39-stimulating compounds as therapies to improve thymic recovery after acute injuries like pre-transplant radiation. The team is currently screening similar compounds to find any that may be more effective.

He and Iovino are also working to determine whether such compounds could help with thymic regeneration in other settings. Unfortunately, our thymuses also slowly shrink and reduce their T-cell output as we age. Dudakov and Iovino would also like to know whether this chronic degeneration could be slowed by boosting the organs regenerative processes.

Our lab is continuing to piece together the molecular players that contribute to thymus regrowth, Dudakov said. Ultimately, we aim to develop therapies that trigger natural regeneration and restore immune health.

###

The study was funded by the National Institutes of Health, the American Society of Hematology and The Rotary Foundation.

Experimental study

Animals

Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice

25-Mar-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read the original post:
Burst of accumulated zinc shows how the mineral boosts immune function, suggesting ways to improve health - EurekAlert

WASHINGTON, DC - House Majority Leader Steny H. Hoyer (MD) released the following statementtodayafter Congressman Fred Upton (MI-06)announcedthat he will not seek re-election at the end of the 117thCongress:

Ive served with Fred Upton for thirty-six years. During that time, Ive known few who have been as faithful to conviction, principle, and duty than Fred, who has represented Michigans Sixth District with great ability and great humility. The people of southwestern Michigan have been well served, and they will surely miss having Fred as their advocate in Washington. I will miss having him as a colleague, though he will certainly remain a friend, a partner in playing Hearts, and a friendly rival during Maryland-Michigan basketball games.Though of different parties, we have found common ground and common causes, and Fred is an individual for whom results and principle matter more than the letter after someones name. That has made him a very effective Member and leader. He has crossed the aisle to join with Democrats on key votes that demonstrated his convictions and values. Fred has always put country over party, including when he stood up for our democracy and to ensure the certification of our elections.

When Fred served as Chairman of the Energy and Commerce Committee, he and I worked together to advance the bipartisan 21st Century CURES Act to fund research at the National Institutes of Health and help find treatments and cures for rare diseases. Earlier in his career he worked to overcome a veto to enact legislation in support of stem cell research that has led to important breakthroughs in health care. I have enjoyed working with Fred to pursue bipartisan solutions and encourage consensus-building in the House as well as serving as Co-Chair with him of the Congressional Friends of Denmark Caucus and traveling overseas together to promote American interests abroad.I join in thanking Fred for his decades of service to Michigan, to the House, and to our country. I wish him and his wife Amey and their family all the best as he prepares to step down at the end of this Congress.

See the rest here:
Hoyer Statement on the Retirement of Congressman Fred Upton - Majority Leader

Stem cell research can be classified into two specific areas: embryonic stem cells and non-embryonic stem cells. Amniotic, induced pluripotent, and adult stem cells do not involve the creation or destruction of a human embryo to have them collected.

Even embryonic stem cells can be collected, to some extent, without the destruction of an embryo. Modern collection techniques include using stem cells that are found in the umbilical cord, in breast milk, or even in bone marrow.

The primary benefit of stem cell research is its clear potential. Since 1868, the idea of using stem cells as a medical treatment has been contemplated in one way or another, especially as we began to understand their full potential. With stem cell therapies, we have the potential to treat injuries, degenerative conditions, or even a genetic disease or disorder.

As for the primary disadvantage of stem cell research, the ethics of collecting embryonic stem cells tends to dominate the conversation. To some people, the idea of destroying an embryo to harvest cells equates to murder. For others, they see the hundreds of thousands of frozen embryos, many of which are simply thrown away after being stored for too long, as wasted potential.

Here are some additional stem cell research pros and cons to review.

1. It could treat several conditions that are virtually untreatable right now. Stem cell research opens numerous avenues for treatments or a cure to be found for several conditions that are either untreatable or without a cure today. Everything from Alzheimers disease to Parkinsons disease to ALS could be improved. People who have a spinal cord injury could receive an injection of stem cells and potentially start the recovery process. Even mental health issues, such as schizophrenia, could one day be treated with stem cell applications.

2. It provides us with greater knowledge. By researching stem cells, we understand more about the growth process of humans. We learn more about how cells form and interact with one another. We can examine pluripotent cells, both induced and embryonic, to see what information is required for them to turn into a specific tissue cell. With a greater understanding of this micro-environment, we can learn more about who we are at our very core.

3. It offers new methods of testing. When new medical treatments are proposed, they must go through multiple stages of testing. This includes animal trials and human trials, which may or may not be successful. As our knowledge of stem cells grows, we could transition testing methods so that only cell populations are examined for a response instead of an innocent animal or a paid human research contributor. That may improve safety, reduce fatalities, and even speed up the approval process.

4. It reduces the risk of rejection. Many stem cell therapies today use the cells that are collected from a patients body. Because the cells are their own, the risk of rejection is reduced or even eliminated. If stem cells could be induced to form into organ tissues, such as a kidney, then the science of organ transplantation could be forever changed. Imagine growing a kidney that is a genetic match instead of trying to find a donor organ that could be rejected, even if a direct match is found. That is the potential of this medical research.

5. It could stop birth defects and mutations before they happen. By understanding the process of stem cell development, it could be possible to change the embryonic development process. Chromosomal concerns, birth defects, and other errors in development could be corrected before birth, giving more newborns a real chance to experience the gift of life. At the same time, the risks of pregnancy loss and health risks to new mothers could be decreased.

1. We have no idea about long-term side effect issues. According to the Canadian Cancer Society, there are several common short-term side effects that are associated with stem cell therapies. They may include infection, bleeding, skin or hair problems, unexplained pain, organ problems, or even the development of a secondary cancer. Every medical treatment provides some risk of a side effect, but this medical technology is so new that we have no idea what the long-term health effects might be.

2. It provides a health risk to everyone involved. Collecting stem cells from an adult carries a medical risk with it. Something could go wrong during the collection process that may reduce the quality of life for the patient. Their life could even be placed at-risk. For embryonic collection, the destruction of the blastocytes that are formed during egg fertilization is required. Since the embryo is technically a different form of human life, there will always be the chance of rejection occurring since the cells are not ones own.

3. Adult stem cells offer limited potential. Our current stem cell research findings indicate that adult stem cells that have already transitioned into specific tissues or formats because of their body location will stay that way. That means stem cells taken from muscle tissue would only be able to create additional muscle tissues. Even if they are induced to be pluripotent, the end result tends to be duplication instead of identification because they have a determined type.

4. It is still an unproven medical technology. There is a lot of hope for stem cell treatments. Hematopoietic stem cell transplantation is performed about 50,000 times annually around the world and the success rate for the treatment is climbing above 90%. Because some forms of stem cell research are classified as illegal or immoral in the United States, however, progress to improve treatments or prove the effectiveness of this medical technology are not as advanced as their potential.

5. It isnt cheap. Stem cell therapies are far from affordable. Because most health insurers classify this type of treatment as experimental, it is rarely a covered procedure. Most treatments that are approved for use in the US cost more than $10,000 per procedure. Some treatment options are six figures. Even the cost of harvesting stem cells from an embryo is a couple thousand dollars. Access to this technology is restricted to socioeconomic means globally and to almost everyone in the United States.

6. Opportunities are limited. Although stem cell research isnt technically forbidden in the US, there are just 19 stem cell lines available for government grants and funding thanks to legislative restrictions that are enacted in 2001. Certain states have begun to draft legislation to completely ban stem cell research, or at least embryonic stem cell research, or at least place major restrictions on the process.

We should examine the ethics of embryonic stem cell research, but we should also examine the benefits it may provide. Adult stem cells, collected from consenting parties, should have no criticism whatsoever. As we move forward in this research, new pros and cons may also require additional contemplation. One thing is for certain: these stem cell research pros and cons show us that humanity is complex, beautiful, and wonderful in many ways.

View original post here:
11 Stem Cell Research Pros and Cons Vittana.org

About the opportunity

The main focus of the Cancer and Stem Cell Laboratory is to study how normal stem cells are transformed into cancer stem cells and to develop effective new therapies that specifically target and destroy cancer stem cells. These cells, which are often resistant to chemotherapy, are now believed to be the engine driving the growth of cancer and the root cause of treatment resistance and relapse.

The Research Associate will conduct the grant-funded project. Some work may require reasonable additional hours from time to time. Depending on qualifications and expertise the applicant may be appointed at levels equivalent to Academic Level A, step 5-8. Initial appointment is for 12 months, however the position may be extended dependent on funding.

The Research Associate is required to design and develop experiments related to single cell technologies in several ongoing stem cell-associated projects. In collaboration with the bioinformatics team, the Research Associate will perform data analysis and will ensure solid interpretation of the data and potential translational applications of these technologies.

This is an exciting opportunity to be on the forefront of applying single cell technologies to crucial questions in advanced stem cell research.

Your key responsibilities will be to:

About you

Closes 11:59 pm Sunday 10 April 2022

To keep our community safe, please be aware of our COVID safety precautions which form our conditions of entry for all staff, students and visitors coming to campus.

Sponsorship / work rights for Australia

Please note: Visa sponsorship is not available for this position. For a continuing position, you must be an Australian or New Zealand citizen or an Australian Permanent Resident.

Australian Temporary Residents currently employed at the University of Sydney may be considered for a fixed term contract for the length of their visa, depending on the requirements of the hiring area and the position.

Pre-employment checks

Your employment is conditional upon the completion of all role required pre-employment or background checks in terms satisfactory to the University. Similarly, your ongoing employment is conditional upon the satisfactory maintenance of all relevant clearances and background check requirements. If you do not meet these conditions, the University may take any necessary step, including the termination of your employment.

EEO statement

At the University of Sydney, our shared values include diversity and inclusion and we strive to be a place where everyone can thrive. We are committed to creating a University community which reflects the wider community that we serve. We deliver on this commitment through our people and culture programs, as well as key strategies to increase participation and support the careers of Aboriginal and Torres Strait Islander People, women, people living with a disability, people from culturally and linguistically diverse backgrounds, and those who identify as LGBTIQ. We welcome applications from candidates from all backgrounds.

How to apply

Applications (including a cover letter, CV, and any additional supporting documentation) can be submitted via the Apply button at the top of the page.

If you are a current employee of the University or a contingent worker with access to Workday, please login into your Workday account and navigate to the Career icon on your Dashboard. Click on USYD Find Jobs and apply.

For a confidential discussion about the role, or if you require reasonable adjustment or support filling out this application, please contact Scott Walker Recruitment Operations, by email to

The University of Sydney

The University reserves the right not to proceed with any appointment.

Click to view the Position Description for this role.

Continued here:
Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 - Times Higher Education

Hey, Google: Remember that stem cell problem you tried to fix in 2019 by banning clinics from advertising unproven therapies on your platform?

The solution didnt last. Clinics have adapted, but you havent, leading to widespread use of your search platform by clinics to pitch risky cell injections.

In response to criticism that Google ads for unproven medical offerings were doing harm, the firm adopted a policy in 2019 banning stem cell clinic advertising on its platform. This positive step was part of a larger move against ads selling unproven therapies. Many of the culprits were clinics touting stem cells as treatments for everything from Alzheimers to stroke.

advertisement

After the ban was implemented, people searching for stem cells for COPD or stem cells for neuropathy, to cite just two examples, would no longer see a slew of ads for clinics offering risky, unproven therapies above the Google search results. That worked for a while. But stem cell clinics and others promoting unproven therapies now effectively game Googles search engine to get new customers.

For example, while stem cell clinics may no longer rely on Google ads to hoist themselves to the top of a search results page, some clinics still dominate large swaths of Google search results related to stem cells. In this way, the company is inadvertently sending many people to these clinics to get risky, unproven injections that generally lack FDA approval and, in my view, have no solid scientific or medical foundation.

advertisement

This weakness in Google search has become a public health issue.

The FDA has been largely ineffective at regulating stem cell clinics. Sure, it has issued warnings to a few. But hundreds of these clinics operate in the U.S., with many more worldwide. I hope the FDA becomes more aggressive in regulating the U.S. clinics and there are signs it might in the future but in the meantime Google has a responsibility to tackle its side of the problem.

Whats the issue more specifically?

For many of the most common stem-cell-related searches, Google often spits out top hits listing either websites for stem cell clinics or promotional sites that direct potential customers back to the clinics. That means if you want to know more about stem cells via Google, the search engine will often point you to the profiteering clinics as the supposed authorities.

Those troubling clinics often outrank the National Institutes of Health, the Food and Drug Administration, universities, and other authoritative sites like the Mayo Clinic in Google search results.

Take the two examples I mentioned earlier: stem cells for neuropathy and stem cells for COPD. As I write this, the number one result in each case is a stem cell clinic, which outranks the American Academy of Neurology, the American Lung Association, the NIH, and other truly authoritative sites. In the case of the neuropathy search, almost every result on the first page is a for-profit clinic selling unproven stem cell injections.

In this way, Google is putting vulnerable people at serious risk. At the very least, thousands of people are losing large amounts of money on generally useless treatments. But its more than that. Weve learned in recent years just how big a health gamble going to stem cell clinics can be with reports of patients being blinded, developing the life-threatening blood infection known as sepsis, or having other serious side effects. In rare cases, people have died.

The stem cell problem with Google and how it handles searches related to other unproven therapies ties back into search engine optimization (SEO). Put simply, SEO basically designs a website to perform in the way that Google thinks is best. The websites with the top SEO will almost always rank highest in Google search results, even if they are selling unproven biomedical offerings.

That has to change.

As it now stands, anyone trying to pitch an unproven therapy in theory just has to pump enough money into SEO and Google will usually rank them highly or at the very top in search results, even if the supposed treatment is bogus or dangerous. Google search has effectively become a form of advertising for sketchy health care. In the worst cases, sites ranking the highest with Google may even be selling non-FDA-approved stem cell therapies that are illegal in the U.S.

Google has known about this problem at least since the spring of 2021, but nothing obvious has changed. At that time, I was able to meet with representatives from Google about my concerns. We had an interesting talk, but I didnt get very far advocating for change.

One thing I did learn is that there are at least two sides to Google, and they dont necessarily connect well with each other. Policy people are on one side. Theyre the ones responsible for the ad ban on the stem cell clinics. The search team is on the other side, and they have a very different perspective on things.

The disconnect between the two is exemplified by the fact that many of the same stem cell clinics now barred from advertising on Google are the same ones whose websites are killing it with Google search and in that way presumably driving loads of customers to their profitable but risky clinics.

The problem related to stem cell clinics is just the tip of the iceberg. What Ive been watching with stem cells is going on much more broadly with health-care-related searches in Google. Its fairly easy to find examples of outright snake oil ranking number one in Google search. For instance, Goops page promoting jade eggs ranks best for a search for jade eggs and above the relevant information page of the Cleveland Clinic, and a search for energy healing delivers a page from a practitioner of energy healing above pages debunking the practice.

Those in charge of Google search might argue thats the way it should be. Perhaps theyd say that hopeful searchers want to be directed to purveyors of unproven health care more than to factual information, as reflected in the patterns of what searchers click on. However, the search engine has a greater responsibility to public health than to follow whatever health care hype is popular at any one particular time with the public.

The bottom line is that when it comes to health and health care, Google search is not as logical or safe as many of us might assume.

I believe that part of what is going on is that Google views its search engine as almost sacred. As a result, perhaps it doesnt want to factor in too many ethical or public safety considerations into how its search engine works.

At this point, however, Google cant afford to view its search engine in that hallowed way when it comes to health care. There are just too many websites out there purveying unproven and even risky treatments that Google nonetheless ranks highly.

Is this a solvable problem? Can Google determine what is an unproven medical offering for sale on a website? Could the company distinguish between ongoing clinical research and marketing unproven therapies? Such things could be challenging, but Im confident Google can figure it all out.

In non-health-care areas, like guides to making weapons of mass destruction or certain kinds of porn, Google already takes into consideration whether websites have questionable or illegal content or products for sale. Such websites generally dont turn up in search results. Making searches related to health care safer should be no less important.

Googles continuing stem cell problem is emblematic of a serious, broader problem with unproven biomedical offerings the company needs to address. The solution seems obvious: Selling an unproven treatment must become a consistent, major negative SEO ranking factor incorporated into the companys algorithms.

Otherwise, Google, youre continuing to enable those who sell unproven and sometimes even dangerous medical products and putting the public at risk.

Paul Knoepfler is a professor at the University of California Davis School of Medicine whose research focuses on stem cells and cancer. He writes about ethics, policy, and other matters on his blog, The Niche. Ads on The Niche are limited to reagents for stem cell researchers, not therapy for patients.

Here is the original post:
Google still has a problem with stem cell and unproven therapies - STAT - STAT

The company is at the forefront of innovating stem cell banking, exploring the science of longevity, and offering disruptive solutions to regenerative medicine through its pioneering healthcare technology. As a result, Medeze is reshaping the way age, illness, and incurable diseases are treated.

"Medeze is one of the most experienced mesenchymal stem cell (MSC) banks in the region. The company garnered this reputation thanks to its R&D department's commitment to high-quality research regarding advanced regenerative medicine," said Azza Fazar, Best Practices Research Analyst at Frost & Sullivan. "Medeze Group captures the surging opportunity in stem cell banking by leveraging its offerings for newborns (cord blood, placentaand cord tissue) and adults (adipose tissueand epithelial cells)."

Medeze addresses the growing needs of people who expect to have healthier and longer lives with its highly differentiated services in an industry that is rapidly evolving. The company is taking advantage of this expanding market with valuable solutions for newborns and adults, including adipose tissue, cord blood, placenta, and cord tissue banking.

In addition, its research and development (R&D) abilities position Medeze as a key player in the market and its first-class research is positively impacting patients that seek stem cell procedures. The company is increasing its services by heavily investing in leading-edge technologies and leveraging this R&D.

"Medeze dedicates its energy to R&D to create high-quality customer offerings. It takes pride in its research-backed offerings, which give physicians and patients the confidence they need when selecting the best stem cell banking solution," noted Fazar. "The company strives to expand its offerings based on the latest technologies, such as stem cell printed cornea and hair follicle banking services."

Each year, Frost & Sullivan presents a Company of the Year award to the organization that demonstrates excellence in terms of growth strategy and implementation in its field. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Frost & Sullivan Best Practices awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion. Contact us: Start the discussion.

Contact:

Kala Mani. S.Email: [emailprotected]

About Medeze

We are creating a standard of practice that is paving the way for a transformation in the way we look at age and illness. We look towards a day when saving newborn stem cells will be a routine practice and stem cell therapy will be the first line of treatment for many of today's incurable diseases. https://www.medezegroup.com/en/

SOURCE Frost & Sullivan

Read this article:
Medeze Named Frost & Sullivan's 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry - PR Newswire

The Bone Marrow-Derived Stem Cells (BMSCS) Market research report additionally researches the market regarding volume and income. The report also wraps the promoters in charge of the development of this market. It likewise includes the restrainers that can hamper the development of this market. Further, report talks about on the worthwhile opportunities that can demonstrate development in the market during the estimated time frame i.e. 2022-2029. The report gives the belief system about various components and tendencies influencing the advancement course of the overall Bone Marrow-Derived Stem Cells (BMSCS) Market. An audit of the effect of the authoritative guidelines and approaches on the Bone Marrow-Derived Stem Cells (BMSCS) Market activities is likewise incorporated into this report.

The Bone Marrow-Derived Stem Cells (BMSCS) Market research report offers a total investigation of focused elements that are changing and puts the clients in front of contenders. For simplicity of understanding and better acknowledgment of market drifts, the worldwide Bone Marrow-Derived Stem Cells (BMSCS) Market report conveys the data at local or topographical level. The report additionally edifies the conceivable effect of government laws and strategies on development are incorporated into the report. Keeping the previously mentioned factors in thought alongside the past and current circumstance of the market, the group of expert investigators has created unsurprising business sector pattern to be trailed by the market for a few up and coming years.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market, By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications) Industry Trends and Forecast to 2029.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

GlobalBone Marrow-Derived Stem Cells (BMSCS)MarketAnalysis and Size

Bone marrow biopsy is increasingly gaining attraction apart from the western economies. Rising incorporation of advanced healthcare technologies in the developing economies all around the world is carving the way for the growth of the market. Owing to the ease of harvesting and multilinear differentiation potential, bone marrow-derived stem cells (BMSCS) market has a bright future.

Data Bridge Market Research analyses that the bone marrow-derived stem cells (BMSCS) market is expected to undergo a CAGR of 10.90% during the forecast period. This indicates that the market value, which was USD 7.45 billion in 2021, would rocket up to USD 17.04 billion by 2029. Sample Preservation and Storage dominates the service type segment of the bone marrow-derived stem cells (BMSCS) market owing to the rising awareness about the practice of preserving blood cell from a new-born baby for future use.

Competitive Landscape andBone Marrow-Derived Stem Cells (BMSCS)Market Share Analysis

The bone marrow-derived stem cells (BMSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to bone marrow-derived stem cells (BMSCS) market.

Some of the major players operating in the bone marrow-derived stem cells (BMSCS) market are:

GlobalBone Marrow-Derived Stem Cells (BMSCS)MarketDefinition

Bone marrow-derived stem cells (BMSCS) are the multipotent adult stem cells with multilineage differentiation potential. Bone marrow-derived stem cells (BMSCS) help in repairing the broken or damaged bone through secretion of factors that stimulate endogenous repair processes.

Bone Marrow-Derived Stem Cells (BMSCS)Market Dynamics

Drivers

Growing prevalence of problems accompanies with the bone marrow diseases all around the globe is one of the major factors responsible for the growth of the market. In other words, rising incidence rate of leukaemia, aplastic anaemia, myeloproliferative disorders, and others is inducing growth of the market.

Rising expenditure for research and development proficiencies especially in the developed and developing economies will further create lucrative market growth opportunities. Research and development proficiencies being conducted for sample analysis and transportation is also bolstering the market growth rate.

Surging number of public private partnerships for the development of healthcare facilities and infrastructure especially in the developing economies is fostering the growth of the market. Rising introduction of novel technologies for the preservation of stem cells and their storage as a collaborative effort of public and private players is further bolstering the growth of the market.

Opportunities

Furthermore, upsurge in the public-private funding for targetresearchactivities, rising awareness about the benefits of , growing awareness on the therapeutic potential of stem cells, rising development of novel technologies for stem cell preservation, processing and storage, rising geriatric population base and rising product innovations and development owing to technological advancements all around the world will extend profitable opportunities for the market players in the forecast period of 2022 to 2029. Additionally, rise in the birth rate, high operational costs associated with stem cell bankingand increasing per capita expenditure on health care will further expand the markets growth rate in the future.

Restraints/Challenges GlobalBone Marrow-Derived Stem Cells (BMSCS)Market

On the other hand, high cost associated with the research and development proficiencies, limited infrastructural facilities, uneven distribution of medical services and dearth of awareness in the backward economies are expected to obstruct market growth. Also, lack of favorable reimbursement scenario and technology penetration in the developing economies, high operational costs associated with stem cell banking, stringent regulatory framework, limited insurance coverage and regulatory compliance, and lack of suitable infrastructure in low- and middle-income countries are projected to challenge the market in the forecast period of 2022-2029.

This bone marrow-derived stem cells (BMSCS) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

COVID-19 Impact onBone Marrow-Derived Stem Cells (BMSCS)Market

COVID-19 had a negative impact on the market. This is because of the significant disruptions experienced by their respective manufacturing companies in the pandemic era. Also, disruptions in the supply-chain operations as a result of various precautionary lockdowns further restricted the growth in this phase. Further the aim of individuals to reduce the non-essential expenses in this pandemic phase narrowed down the scope of growth. Also, restrictions imposed on the movement further created hindrances. However, the future of the market is in good shape.

Table of Contents-Snapshot

Executive Summary

Chapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

For More Insights Get Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

GlobalBone Marrow-Derived Stem Cells (BMSCS)Market Scope

The bone marrow-derived stem cells (BMSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Service type

Based on service type, bone marrow-derived stem cells (BMSCS) market is segmented into sample preservation and storage, sample analysis, sample processing, sample collection and transportation.

Application

Bone marrow-derived stemcells(BMSCS) market has also been segmented based on the application into personalized banking applications, research applications and clinical applications. Research applications have been further segmented into disease treatment studies, life science research and drug discovery. Clinical applications have been further segmented into hematopoietic disorders, autoimmune disorders and other diseases.

Read [emailprotected] https://www.databridgemarketresearch.com/reports/global-bone-marrow-derived-stem-cells-bmscs-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Here is the original post:
Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry...